RedHill Biopharma (RDHL) Operating Margin (2012 - 2023)

RedHill Biopharma (RDHL) has 11 years of Operating Margin data on file, last reported at 2992.87% in Q2 2023.

• Operating Margin for Q2 2023 came in at 2992.87%, up 294295.0% year-over-year; the trailing twelve-month figure through Jun 2023 was 122.98% (up 797.0% YoY), and the FY2025 annual result was 2776.92%, down 269642.0% from the prior year.
• Operating Margin rose to 2992.87% in Q2 2023 per RDHL's latest filing, from 808.0% in the prior quarter.
• Over five years, Operating Margin peaked at 2992.87% in Q2 2023 and troughed at 808.0% in Q1 2023.
• A 5-year average of 336.14% and a median of 90.03% in 2020 frame the typical range for Operating Margin.
• The sharpest annual moves came in 2021 and 2023: Operating Margin sank 152314 bps in 2021, then jumped 294295 bps in 2023.
• A 5-year view of Operating Margin shows it stood at 739.87% in 2019, then plunged by 88 bps to 91.83% in 2020, then sank by 798 bps to 641.43% in 2021, then advanced by 8 bps to 591.81% in 2022, then soared by 606 bps to 2992.87% in 2023.
• Business Quant data shows RDHL's Operating Margin at 2992.87% in Q2 2023, 808.0% in Q1 2023, and 591.81% in Q4 2022.